May 10, 2017 - Supplement: CDK4/6 Inhibitors   (View All Issues)

Solid Tumors

Geoffrey I. Shapiro, MD, PhD, Guest Editor  / May 10, 2017 - Supplement: CDK4/6 Inhibitors

Introduction: CDK4/6 Inhibitors: Moving Beyond the Breast Cancer Setting

The novel mechanism of action of drugs that inhibit the cyclin D–dependent kinases CDK4 and CDK6 has prompted effective new treatment strategies. Although the bulk of the data supporting the use of selective CDK4/6 inhibitors is currently in breast cancer, patients with other tumor types are...

Solid Tumors

Caroline Helwick  / May 10, 2017 - Supplement: CDK4/6 Inhibitors

CDK4/6 Inhibitors: Their Role in Breast Cancer

The robust progression-free survival benefits achieved with the use of the CDK4/6 inhibitors palbociclib or ribociclib in the metastatic setting provided the impetus to study these agents in early-stage breast cancer. Adjuvant studies are underway, but they take time to mature. For evaluating...

Solid Tumors

The ASCO Post  / May 10, 2017 - Supplement: CDK4/6 Inhibitors

CDK4/6 Inhibitors: Where They Are Now and Where They Are Headed in the Future

Geoffrey I. Shapiro, MD, PhD, Director of the Early Drug Development Center at the Dana-Farber Cancer Institute, Boston, explained the current research initiatives involving cyclin D–dependent kinase (CDK) 4/6 inhibitors.

Mechanism of Action

How do CDK4/6 inhibitors work at the cellular level in...

Solid Tumors

Caroline Helwick  / May 10, 2017 - Supplement: CDK4/6 Inhibitors

First-in-Human Experience With Abemaciclib

The investigational cyclin D–dependent kinase (CDK) 4/6 inhibitor abemaciclib was recently evaluated in several solid tumor types in a phase I multicenter trial.¹ Given primarily as a single agent and with continuous dosing, abemaciclib showed encouraging early signals of clinical activity not only ...

Solid Tumors

Liz Janetschek  / May 10, 2017 - Supplement: CDK4/6 Inhibitors

Selected Clinical Trials of CDK4/6 Inhibitors

This Clinical Trials Resource Guide includes a selection of actively recruiting clinical trials of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, including palbociclib, ribociclib, and abemaciclib in multiple tumor types. All of the studies here and many others are listed on the National...